| Officer | Age | Source |
|---|---|---|
|
Steve Forte
Also a director
EVP, CHIEF FINANCIAL OFFICER
Title from the Form 4 dated Jan 28, 2026
|
46 | |
|
Sandra Isabelle Barros Alves
SVP, Finance and CAO
Title from the Form 4 dated Jan 28, 2026
|
Not stated | |
|
Alves
Senior Vice President, Chief Accounting Officer and principal accounting officer
|
Not stated | |
|
Jon Adkins
Also a director
Executive officer
|
Not stated |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 29, 2025 · updated by the 8-K of Jan 28, 2026
| Director | Age | On board | Independent | Committees | Other public boards | 2024 pay | Source |
|---|---|---|---|---|---|---|---|
|
Thomas Civik
Board chair
|
56 |
2021
4 years
|
Independent | None stated | Pyxis Oncology, Inc. | $149,201 | |
|
Steve Forte
CEO
|
46 |
2025
this year
|
Not independent | None stated | None stated | Paid as CEO | |
|
David Bonita, M.D.
|
49 |
2019
6 years
|
Independent |
Compensation
Science and Technology
|
Acutus Medical Inc., Ikena Oncology, Inc., Prelude Therapeutics Inc., Third Harmonic Bio, Inc. | $119,060 | |
|
Carol A. Schafer
|
61 |
2019
6 years
|
Independent |
Nominating and Corporate Governance · Chair
|
Immunome, Inc., Insmed, Inc, Kura Oncology, Inc. | $128,806 | |
|
Steven Stein, M.D.
|
58 |
2024
1 year
|
Independent | None stated | None stated | $172,311 | |
|
Samarth Kulkarni, Ph.D.
|
46 |
2019
6 years
|
Independent | None stated | Black Diamond Therapeutics, Inc., Oruka Therapeutics, Centessa Pharmaceuticals plc | $118,430 | |
|
Susan M. Molineaux, Ph.D.
|
71 |
2023
2 years
|
Independent | None stated | Geron Corporation | $122,847 | |
|
Ann D. Rhoads
|
59 |
2020
5 years
|
Independent |
Audit · Chair
|
Globus Medical Inc., QuidelOrtho Corporation (formerly Quidel Corporation), iTeos Therapeutics Inc. | $130,138 | |
|
Jon Adkins
Joined Jan 28, 2026
|
- | - | - | - | - | - |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
The proxy filed Apr 29, 2025 describes a review policy but reports no transactions.
Read the policy in the proxyLoading...